Clinical Trial Update: Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating empagliflozin to prevent anthracycline-induced cardiotoxicity in cancer patients; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiotoxicity

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Cardiotoxicity | Phase 3 | Status: RECRUITING